Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
M.D. Anderson Cancer Center National Cancer Institute (NCI) Schering-Plough |
---|---|
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00102635 |
The primary objective of this study is to estimate the modulation of intermediate biological endpoints of the combination of 4-HPR and SCH66336, a farnesyl transferase inhibitor (FTI), across 4 randomly assigned dose levels in patients with locally advanced or recurrent head and neck cancer. We will also assess the activity, safety, tolerability and side effects of 4-HPR/SCH66336 and hope to establish a phase II regimen.
Condition | Intervention | Phase |
---|---|---|
Head and Neck Cancer |
Drug: fenretinide (4-HPR) Drug: SCH66336 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Bio-availability Study |
Official Title: | A Phase IB Randomized Translational Study of Fenretinide (4-HPR) in Combination With SCH66336, a Farnesyl Transferase Inhibitor, in Patients With Advanced or Recurrent Head and Neck Cancer |
Estimated Enrollment: | 40 |
Study Start Date: | January 2005 |
Estimated Study Completion Date: | November 2006 |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |
MD Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Edward S Kim, MD | M.D. Anderson Cancer Center |
Study ID Numbers: | ID01-455 |
Study First Received: | January 31, 2005 |
Last Updated: | November 13, 2006 |
ClinicalTrials.gov Identifier: | NCT00102635 |
Health Authority: | United States: Food and Drug Administration |
Epidermoid carcinoma Squamous cell carcinoma Head and Neck Neoplasms Carcinoma, squamous cell Fenretinide Neoplasms, Squamous Cell |
Carcinoma, Squamous Cell Carcinoma, squamous cell of head and neck Recurrence Neoplasms, Glandular and Epithelial Carcinoma |
Anticarcinogenic Agents Neoplasms Neoplasms by Site Neoplasms by Histologic Type Antineoplastic Agents |
Therapeutic Uses Physiological Effects of Drugs Protective Agents Pharmacologic Actions |